Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$96.23M, compared with -$114.33M a year earlier. Trailing-twelve-month net income was -$394.6M.
Context
- Net income amounted to 609.9% of revenue in FY2025, down 286.9 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of -$358.84M (+13.1%) for the fiscal year ending Dec 2026, a slowdown from the +20.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$96.23M-0.5% QoQ
- Last fiscal yearDec 2025
- -$412.69M+20.5% YoY
- LTMMar 2026
- -$394.6M+25.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.8% | -10.7% | -26.5 pp |
| 1 year | +20.5% | +13.1% | -7.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (412.69M) USD
- Year-over-year change
- +20.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (412.69M) | +20.5% |
| FY2024 | 2024-12-31 | (519.02M) | -7.9% |
| FY2023 | 2023-12-31 | (481.19M) | -1.5% |
| FY2022 | 2022-12-31 | (474.19M) | -77.0% |
| FY2021 | 2021-12-31 | (267.89M) | — |
Net Income vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 net income of -$394.6M is the 9th highest of the 10 companies compared; the peer median is -$157.71M.
- Its year-over-year change of +25.0% is the 4th highest of 10, against a peer median of +9.9%.
- Net income amounts to 597.0% of revenue for NTLA, versus a peer median of 281.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | -$85.43M | +78.6% | — | 54.7% | |
| LTM Mar 2026 | -$108.95M | +56.6% | — | 281.6% | |
| LTM Mar 2026 | -$120.53M | +28.0% | — | 151.1% | |
| LTM Mar 2026 | -$133.22M | +9.9% | — | 1189.1% | |
| LTM Jun 2026 | -$157.71M | -26.7% | — | 184.0% | |
| LTM Mar 2026 | -$208.87M | +4.0% | — | 1154.4% | |
| LTM Mar 2026 | -$209.38M | +18.9% | — | — | |
| LTM Mar 2026 | -$241.99M | -16.0% | — | — | |
| LTM Mar 2026 | -$394.6M | +25.0% | — | 597.0% | |
| LTM Sep 2026 | -$456.14M | +6.6% | — | 1812.1% | |
| Peer median (excluding NTLA) | -$157.71M | +9.9% | — | 281.6% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.